Tectonic Therapeutic Future Growth
Future criteria checks 0/6
Tectonic Therapeutic's earnings are forecast to decline at 27.8% per annum. EPS is expected to grow by 15.1% per annum.
Key information
-27.8%
Earnings growth rate
15.1%
EPS growth rate
Biotechs earnings growth | 30.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 24 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -81 | -86 | N/A | 3 |
12/31/2025 | N/A | -67 | -67 | N/A | 3 |
12/31/2024 | N/A | -57 | -57 | N/A | 3 |
3/31/2024 | N/A | -44 | -39 | -39 | N/A |
12/31/2023 | N/A | -43 | -41 | -41 | N/A |
9/30/2023 | N/A | -45 | -37 | -37 | N/A |
12/31/2022 | N/A | -32 | -30 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TECX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TECX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if TECX's revenue is forecast to grow faster than the US market.
High Growth Revenue: TECX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TECX's Return on Equity is forecast to be high in 3 years time